265
Participants
Start Date
October 27, 2022
Primary Completion Date
January 31, 2025
Study Completion Date
March 31, 2025
fruquintinib+sintilimab
fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle.
axitinib / everolimus
axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion based on clinical; everolimus, 10 mg, QD, PO, 3 weeks/cycle.
fruquintinib
fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle.
Beijing Chao-Yang Hospital, Capital Medical University, Beijing
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Peking Union Medical College Hospital, Beijing
Peking University First Hospital, Beijing
Peking University Third Hospital, Beijing
The First Affiliated Hospital of Bengbu Medical College, Bengbu
The First Hospital of Jilin University, Changchun
Hunan Cancer Hospital, Changsha
Xiangya Hospital Central South University, Changsha
Sichuan Provincial People's Hospital, Chengdu
West China Hospital of Sichuan University, Chengdu
Chongqing University Cancer Hospital, Chongqing
The First Affilated Hospital of Fujian Medical University, Fuzhou
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
Sun Yat-sen University Cancer Center, Guangzhou
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
The First Affiliated Hospital, Zhejiang University, Hangzhou
Harbin Medical University Cancer Hospital, Ha’erbin
Anhui Provincial Hospital, Hefei
The First Affiliated Hospital of Anhui Medical University, Hefei
Qilu Hospital of Shandong University, Jinan
Shandong Cancer Hospital & Institute, Jinan
Yunnan Cancer Hospital, Kunming
Lanzhou University Second Hospital, Lanzhou
The First Affiliated Hospital of Nanchang University, Nanchang
Jiangsu Cancer Hospital, Nanjing
Jiangsu Province Hospital, Nanjing
Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing
Guangxi Medical University Cancer Hospital, Nanning
Nantong Tumor Hospital, Nantong
The Affiliated Hospital of Qingdao University, Qingdao
Fudan University Shanghai Cancer Center, Shanghai
Renji Hospital,Shanghai Jiaotong University School of Medicine, Shanghai
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
Shanghai General Hospital, Shanghai
Zhongshan Hospital Fudan University, Shanghai
Liaoning Cancer Hospital & Institution, Shenyang
The First Hospital of China Medical University, Shenyang
The Second Hospital of Tianjin Medical University, Tianjin
Tianjin Medical University Cancer Institute & Hospital, Tianjin
The First Affiliated Hospital of Wenzhou medical university, Wenzhou
Tongji Hospital Tongji Medical College of HUST, Wuhan
Wuhan Union Hospital of China, Wuhan
The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal), Xi'an
The First Affiliated Hospital of Xiamen University, Xiamen
Henan Cancer Hospital, Zhengzhou
Henan Provincial People's Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Lead Sponsor
Hutchmed
INDUSTRY